| Index | S&P 500 | P/E | — | EPS (ttm) | -4.85 | Insider Own | 1.51% | Shs Outstand | 48.17M | Perf Week | -5.24% |
| Market Cap | 16.31B | Forward P/E | 26.46 | EPS next Y | 12.80 | Insider Trans | -26.54% | Shs Float | 47.20M | Perf Month | 16.66% |
| Enterprise Value | 19.14B | PEG | — | EPS next Q | 2.97 | Short Float | 6.00% | Perf Quarter | 44.60% | ||
| Income | -239.00M | P/S | 4.08 | EPS this Y | 11.11% | Short Ratio | 2.98 | Perf Half Y | 96.46% | ||
| Sales | 4.00B | P/B | 5.73 | EPS next Y | 12.45% | ROA | -3.17% | Short Interest | 2.83M | Perf YTD | 69.71% |
| Book/sh | 59.09 | P/C | 84.93 | EPS next 5Y | 11.60% | ROE | -7.72% | 52W High | 379.63 -10.82% | Perf Year | 89.01% |
| Cash/sh | 3.99 | P/FCF | 43.95 | EPS past 3/5Y | — | ROIC | 7.72% | 52W Low | 146.20 131.56% | Perf 3Y | 93.37% |
| Dividend Est. | — | EV/EBITDA | 86.62 | Sales past 3/5Y | 0.33% 6.55% | Gross Margin | 32.24% | Volatility | 5.04% 4.81% | Perf 5Y | -20.12% |
| Dividend TTM | — | EV/Sales | 4.79 | EPS Y/Y TTM | — | Oper. Margin | 12.35% | ATR (14) | 15.41 | Perf 10Y | 312.20% |
| Dividend Ex-Date | — | Quick Ratio | 1.04 | Sales Y/Y TTM | -0.74% | Profit Margin | -5.96% | RSI (14) | 56.21 | Recom | 2.24 |
| Dividend Gr. 3/5Y | — | Current Ratio | 1.35 | EPS Q/Q | -3.21% | SMA20 | 3.79% | Beta | 1.32 | Target Price | 308.36 |
| Payout | 0.00% | Debt/Eq | 1.06 | Sales Q/Q | -2.71% | SMA50 | 11.81% | Rel Volume | 1.53 | Prev Close | 359.41 |
| Employees | 19,000 | LT Debt/Eq | 1.06 | Earnings | Nov 04 | SMA200 | 52.25% | Avg Volume | 1.05M | Price | 338.54 |
| IPO Date | Jun 23, 2000 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 10.14% 2.75% | Net Debt/EBITDA | 12.83 | Volume | 1,604,507 | Change | -5.81% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Sep-30-26 | Resumed | UBS | Neutral | $357 |
| Sep-28-26 | Reiterated | Jefferies | Buy | $195 → $340 |
| Sep-25-26 | Reiterated | Robert W. Baird | $291 → $334 | |
| Sep-25-26 | Reiterated | Evercore ISI Group | Outperform | $320 → $330 |
| Sep-25-26 | Reiterated | Deutsche Bank | Buy | $240 → $320 |
| Sep-25-26 | Reiterated | Mizuho | Neutral | $264 → $295 |
| Sep-25-26 | Reiterated | Barclays | Overweight | $300 → $330 |
| Sep-25-26 | Reiterated | RBC Capital | Outperform | $282 → $322 |
| Sep-17-26 | Reiterated | Argus Research | Hold | $250 → $330 |
| Sep-11-26 | Reiterated | Evercore ISI Group | Outperform | $220 → $320 |
Charles River Laboratories International, Inc. operates as a contract research organization (CRO), providing essential preclinical services to the pharmaceutical and biotechnology industries. Its core business revolves around assisting clients with drug discovery, non-clinical development, and thorough safety testing, with its services extending globally across the United States, Europe, Canada, and the Asia Pacific region. The company organizes its diverse offerings into three principal segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions. 1. Research Models and Services (RMS): This division is a key supplier of high-quality rodent research models, including specially bred strains of rats and mice for experimental purposes. It also offers a comprehensive array of support services to help clients effectively utilize these models in their research and for the screening of potential non-clinical drug candidates. These include providing genetically engineered models, insourcing solutions for facility management, and diagnostic services for research animals. 2. Discovery and Safety Assessment (DSA): The DSA segment plays a crucial role in advancing early-stage drug pipelines. It delivers early-phase and in vivo discovery services focused on identifying and validating new therapeutic targets, chemical compounds, and antibodies. The ultimate goal is to prepare promising non-clinical drug and therapeutic candidates for subsequent safety evaluations. Additionally, this segment provides an extensive range of safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism studies, and pharmacokinetics. 3. Manufacturing Solutions: This segment addresses critical quality control requirements by offering in vitro methods for both routine and rapid testing of the quality of sterile and non-sterile pharmaceuticals, as well as consumer products. It also serves as a vital provider of specialized biologics testing, which is often outsourced by pharmaceutical and biotechnology companies. Furthermore, the segment supplies avian vaccine services, including specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products, all essential for vaccine production. Beyond these specialized segments, Charles River also manages contract vivarium operations, providing crucial animal housing and care facilities for its biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/27/2025 | FY 2024 12/28/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 3,999 | 4,015 | 4,050 | 4,129 | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 2,710 | 2,790 | 2,718 | 2,627 | — | — | — | — | — | |
| Gross Profit | 1,289 | 1,226 | 1,332 | 1,503 | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 754 | 743 | 751 | 748 | — | — | — | — | — | |
| Research and Development | 0 | 0 | 0 | 0 | — | — | — | — | — | |
| Other Operating Expense | 41 | -25 | 353 | 137 | — | — | — | — | — | |
| Operating Income | 494 | 508 | 227 | 617 | — | — | — | — | — | |
| Interest Expense | 106 | 107 | 126 | 137 | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | -571 | -500 | -8 | 101 | — | — | — | — | — | |
| Net Income Before Taxes | -184 | -100 | 93 | 581 | — | — | — | — | — | |
| Income Taxes | 53 | 43 | 68 | 101 | — | — | — | — | — | |
| Consolidated Net Income | -239 | -144 | 10 | 475 | — | — | — | — | — | |
| Net Income From Continuing Operations | -236 | -142 | 25 | 480 | — | — | — | — | — | |
| Net Income | -239 | -144 | 10 | 475 | — | — | — | — | — | |
| EPS (Recurring) | -4.84 | -2.91 | 0.20 | 9.27 | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -4.84 | -2.91 | 0.20 | 9.27 | — | — | — | — | — | |
| EPS (Diluted) | -4.85 | -2.91 | 0.20 | 9.22 | — | — | — | — | — | |
| EBITDA | 221 | 411 | 581 | 1,032 | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | 930.80 | 25.64 | — | — | — | — | — | |
| Price To Sales Ratio | 4.06 | 2.54 | 2.34 | 2.92 | — | — | — | — | — | |
| Gross Margin | 32.23 | 30.54 | 32.89 | 36.40 | — | — | — | — | — | |
| Operating Margin | 12.35 | 12.65 | 5.60 | 14.94 | — | — | — | — | — | |
| Net Margin | -5.98 | -3.59 | 0.25 | 11.50 | — | — | — | — | — | |
| Shares Outstanding | 48 | 50 | 51 | 51 | — | — | — | — | — | |
| Market Capitalization | 16,250 | 10,183 | 9,494 | 12,056 | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| FOSTER JAMES C | Director | Oct 22 '26 | Sale | 350.00 | 24,042 | 8,414,700 | 31,596 | Oct 26 |
| FOSTER JAMES C | Director | Oct 22 '26 | Option Exercise | 244.41 | 24,042 | 5,876,105 | 55,638 | Oct 26 |
| Parisotto Shannon M | CEVP, Disc & Safety Assessment | Oct 21 '26 | Sale | 344.41 | 2,156 | 742,548 | 4,807 | Oct 23 |
| Parisotto Shannon M | CEVP, Disc & Safety Assessment | Oct 21 '26 | Option Exercise | 244.41 | 2,156 | 526,948 | 6,963 | Oct 23 |
| Parisotto Shannon M | CEVP, Disc & Safety Assessment | Oct 05 '26 | Option Exercise | 208.44 | 981 | 204,480 | 5,788 | Oct 07 |
| Parisotto Shannon M | CEVP, Disc & Safety Assessment | Oct 05 '26 | Sale | 308.44 | 981 | 302,580 | 4,807 | Oct 07 |
| Coleman Glenn | EVP & Chief Financial Officer | Sep 30 '26 | Buy | 297.43 | 10 | 2,974 | 27,762 | Oct 02 |
| FOSTER JAMES C | Director | Aug 25 '26 | Sale | 300.00 | 33,561 | 10,068,300 | 31,596 | Aug 27 |
| FOSTER JAMES C | Director | Aug 25 '26 | Option Exercise | 199.42 | 33,561 | 6,692,845 | 65,157 | Aug 27 |
| Parisotto Shannon M | CEVP, Disc & Safety Assessment | Aug 19 '26 | Option Exercise | 194.12 | 2,039 | 395,811 | 6,846 | Aug 20 |
| Parisotto Shannon M | CEVP, Disc & Safety Assessment | Aug 19 '26 | Sale | 294.12 | 2,039 | 599,711 | 4,807 | Aug 20 |
| Andrews Nancy C | Director | Aug 18 '26 | Option Exercise | 164.30 | 573 | 94,144 | 2,011 | Aug 20 |
| Andrews Nancy C | Director | Aug 18 '26 | Sale | 285.24 | 573 | 163,443 | 1,438 | Aug 20 |
| Girshick Birgit | Chief Executive Officer | Aug 11 '26 | Option Exercise | 179.66 | 6,500 | 1,167,790 | 42,513 | Aug 13 |
| Girshick Birgit | Chief Executive Officer | Aug 11 '26 | Sale | 279.90 | 6,500 | 1,819,350 | 36,013 | Aug 13 |